FindTrial
Sign In

linagliptin placebo

DRUG6 trials

Sponsors

Boehringer Ingelheim, University Hospital, Gentofte, Copenhagen

Conditions

Diabetes Mellitus, Type 2Type 2 Diabetes

Phase 3

A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate
CompletedNCT00740051
Boehringer IngelheimDiabetes Mellitus, Type 2
Start: 2008-08-31Updated: 2014-06-27
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
CompletedNCT01243424
Boehringer IngelheimDiabetes Mellitus, Type 2
Start: 2010-11-11End: 2018-08-21Updated: 2020-01-07
Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
CompletedNCT01422876
Boehringer IngelheimDiabetes Mellitus, Type 2
Start: 2011-08-31End: 2013-09-30Updated: 2015-04-02
Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus
CompletedNCT02453555
Boehringer IngelheimDiabetes Mellitus, Type 2
Start: 2015-05-14End: 2017-03-27Updated: 2019-02-15

Phase 4

Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
CompletedNCT01438814
Boehringer IngelheimDiabetes Mellitus, Type 2
Start: 2011-11-30End: 2013-03-31Updated: 2014-11-25

Unknown Phase

The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors
CompletedNCT02792400
University Hospital, Gentofte, CopenhagenType 2 Diabetes
Start: 2016-05-31End: 2018-07-31Updated: 2020-04-08

Related Papers

Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin
JAMA Cardiology2024-01-0313 citations
Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials
Stroke2023-07-149 citations
Chronic kidney disease and cognitive decline in patients with type 2 diabetes at elevated cardiovascular risk
Journal of Diabetes and its Complications2022-08-313 citations
Females with type 2 diabetes are at higher risk for accelerated cognitive decline than males: CAROLINA-COGNITION study.
2021-10-2724 citations
Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study.
2021-02-0932 citations
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes
JAMA2019-09-19576 citations
Linagliptin as add‐on to empagliflozin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two‐part, randomized, placebo‐controlled trial
Diabetes Obesity and Metabolism2018-08-0914 citations
Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials.
2018-06-158 citations
Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
2018-06-0134 citations
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA<sup>®</sup>): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.
2018-03-1455 citations
Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus
Expert Opinion on Pharmacotherapy2017-04-045 citations
A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes
Cardiovascular Diabetology2017-01-2137 citations
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA<sup>®</sup>)
Diabetes and Vascular Disease Research2015-03-15204 citations
P4‐331: RELATIONSHIP BETWEEN GLYCAEMIC CONTROL AND COGNITIVE FUNCTION IN PATIENTS WITH TYPE 2 DIABETES AT ELEVATED CARDIOVASCULAR RISK
Alzheimer s & Dementia2014-07-011 citations
Cardiovascular Safety of Linagliptin Demonstrated in Pooled Analysis
MD Conference Express2013-11-01
Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus
Expert Review of Endocrinology & Metabolism2013-07-01
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
2012-10-0145 citations